PharmaShots Weekly Snapshots (September 30 – October 04, 2024)
This week PharmaShots’ news was all about the updates on Clinical Trials, Pharma, Biotech, COVID-19, Regulatory & MedTech. Check out our full report below:
BMS Reports Data from P-IIIb/IV (PSORIATYK SCALP) and Real-World (RePhlect) Studies of Sotyktu for Moderate-to-Severe Scalp Psoriasis
Read More: BMS
Merus Reports the First Patient Dosing in P-III (LiGeR-HN1) Study of Petosemtamab Plus Keytruda for 1L Treatment of R/M Head and Neck Squamous Cell Carcinoma (HNSCC)
Read More: Merus
UroGen Reports the First Patient Dosing with UGN-103 in P-III (UTOPIA) Study to Treat Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Read More: UroGen
Johnson & Johnson Highlights the Real-World Study of Erleada (Apalutamide) for Treating Metastatic Castration-Sensitive Prostate Cancer at ECOP 2024
Read More: Johnson & Johnson
AbbVie Seeks the US FDA’s Accelerated Approval of Telisotuzumab Vedotin (Teliso-V) for Treating Non-Squamous NSCLC
Read More: AbbVie
Sanofi and Regeneron’s Dupixent Receives the US FDA’s and NMPA’s Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)
Read More: Sanofi & Regeneron
Astria Therapeutics’ Navenibart Gains the US FDA’s Orphan Drug Designation to Treat Hereditary Angioedema
Read More: Astria Therapeutics
Johnson & Johnson Submits sBLA of Darzalex Faspro Regimen to the US FDA for Newly Diagnosed Multiple Myeloma Patients
Read More: Johnson & Johnson
AstraZeneca and Daiichi Sankyo Report the US FDA’s sBLA Acceptance of Enhertu with Priority Review to Treat HR+/HER2-low Metastatic Breast Cancer
Read More: AstraZeneca & Daiichi Sankyo
AstraZeneca Reports the US FDA’s sNDA Acceptance of Calquence with Priority Review for Mantle Cell Lymphoma
Read More: AstraZeneca
Sagimet’s Denifanstat Gains the US FDA’s Breakthrough Therapy Designation to Treat Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Read More: Sagimet
BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)
Read More: BMS
Daiichi Sankyo Reports the sNDA Submission of Enhertu to Treat HER2 Low or Ultralow Metastatic Breast Cancer in Japan
Read More: Daiichi Sankyo
Genentech Reports the Acquisition of Regor's CDK Inhibitors Portfolio Targeting Breast Cancer
Read More: Genentech & Regor
Recordati to Acquire Sanofi’s Enjaymo, Enhancing its Rare Diseases Portfolio
Read More: Recordati & Sanofi
Prime Medicine and BMS Join Forces to Develop and Commercialize Various Prime Edited Ex Vivo T-Cell Therapies
Read More: Prime Medicine & BMS
ABL Bio Collaborates with Merck to Develop ABL103 Plus Keytruda for Treating Solid Tumors
Read More: ABL Bio & Merck
Organon and Shanghai Henlius Biotech Provides Update on P-III Trial of HLX11 (Biosimilar, Perjeta)
Read More: Organon & Shanghai Henlius Biotech
Fresenius Kabi and Formycon Report the US FDA’s Approval of Otulfi (Biosimilar, Stelara)
Read More: Fresenius Kabi & Formycon
Teva and mAbxience Join Forces on Second Biosimilar Candidate in Oncology
Read More: Teva & mAbxience
Elucid Reports the US FDA’s Approval of PlaqueIQ Image Analysis Software for Cardiovascular Disease Evaluation
Read More: Elucid
SetPoint Medical Reports the US FDA’s IDE Approval to Initiate Neuroimmune Modulation Platform’s Evaluation for Relapsing-Remitting Multiple Sclerosis
Read More: SetPiont Medical
OrthAlign Reports the US FDA’s Approval of Lantern Hip Technology for Hip Arthroplasty
Read More: OrthAlign
Merck Animal Health Reports the Launch of SENSEHUB Cow Calf Remote Monitoring Technology
Read More: Merck Animal Health
Related Post: PharmaShots Weekly Snapshots (September 23 – September 27, 2024)
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.